Going Beyond Immunotherapy in HPV-Negative Head and Neck Squamous Cell Carcinoma

Deborah J. Wong, MD, PhD, discusses data with ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC.

Kevin Harrington, MBBS, MRCP, FRCR, FRCP, PhD, DIC, discusses ficerafusp alfa for the treatment of patients with HPV-negative head and neck cancer.

Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.

Ficerafusp alfa plus pembrolizumab elicited deep responses in HPV-negative recurrent or metastatic head and neck cancer.